| Vaccine description | |
|---|---|
| Target | Chikungunya virus |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | Ixchiq |
| AHFS/Drugs.com | Ixchiq |
| License data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status | |
A Chikungunya vaccine is a vaccine intended to provide acquired immunity against the chikungunya virus.[3]
The most commonly reported side effects include headache, fatigue, muscle pain, joint pain, fever, nausea and tenderness at the injection site.[6]
The first chikungunya vaccine was approved for medical use in the United States in November 2023.[6]
- ^ "Register Of Innovative Drugs [Updated: 2024-07-04]". Health Canada. 4 July 2024. Retrieved 15 July 2024.
- ^ "Ixchiq Product information". Health Canada. 20 June 2024. Retrieved 15 July 2024.
- ^ a b "Ixchiq". U.S. Food and Drug Administration. 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023.
This article incorporates text from this source, which is in the public domain.
- ^ Cite error: The named reference
Ixchiq EPARwas invoked but never defined (see the help page). - ^ Cite error: The named reference
Ixchiq PIwas invoked but never defined (see the help page). - ^ a b "FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus". U.S. Food and Drug Administration (Press release). 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023. This article incorporates text from this source, which is in the public domain.
